{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:56:34Z","timestamp":1780466194069,"version":"3.54.1"},"reference-count":85,"publisher":"FapUNIFESP (SciELO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Neuro-Psiquiatr."],"abstract":"<jats:p>ABSTRACT Transthyretin familial amyloid polyneuropathy is an autosomal dominant inherited sensorimotor and autonomic polyneuropathy, which if untreated, leads to death in approximately 10 years. In Brazil, liver transplant and tafamidis are the only disease-modifying treatments available. This review consists of a consensus for the diagnosis, management and treatment for transthyretin familial amyloid polyneuropathy from the Peripheral Neuropathy Scientific Department of the Brazilian Academy of Neurology. The first and last authors produced a draft summarizing the main views on the subject and emailed the text to 10 other specialists. Relevant literature on this subject was reviewed by each participant and used for the individual review of the whole text. Each participant was expected to review the text and send a feedback review by e-mail. Thereafter, the 12 panelists got together at the city of Fortaleza, discussed the controversial points, and reached a consensus for the final text.<\/jats:p>","DOI":"10.1590\/0004-282x20180094","type":"journal-article","created":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T13:31:11Z","timestamp":1539955871000},"page":"609-621","source":"Crossref","is-referenced-by-count":23,"title":["Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy"],"prefix":"10.1590","volume":"76","author":[{"given":"Marcus Vinicius","family":"Pinto","sequence":"first","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amilton Antunes","family":"Barreira","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Acary Souza","family":"Bulle","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Raimundo Gomes de","family":"Freitas","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcondes Cavalcante","family":"Fran\u00e7a Jr","sequence":"additional","affiliation":[{"name":"Universidade de Campinas,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco de Assis Aquino","family":"Gondim","sequence":"additional","affiliation":[{"name":"Universidade Federal do Cear\u00e1,  Brasil; Centro Universit\u00e1rio Unichristus,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Domenico","family":"Marrone","sequence":"additional","affiliation":[{"name":"PUCRS,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Marques Jr","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osvaldo J. M.","family":"Nascimento","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Tellechea","family":"Rotta","sequence":"additional","affiliation":[{"name":"Hospital Moinhos de Vento,  Brasil; Santa Casa de Miseric\u00f3rdia de Porto Alegre,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Pupe","sequence":"additional","affiliation":[{"name":"Universidade Federal Fluminense,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia","family":"Waddington-Cruz","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio de Janeiro,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2018,9]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima Y","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/mus.20821","article-title":"The molecular biology and clinical features of amyloid neuropathy","volume":"36","author":"Benson MD","year":"2007","journal-title":"Muscle Nerve"},{"key":"ref3","series-title":"Amyloid and amyloidosis","first-page":"88","volume-title":"Forty years of experience with type I amyloid neuropathy: review of 483 cases","author":"Coutinho PD","year":"1980"},{"issue":"sup1 Suppl 1","key":"ref4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/13506129.2012.673183","article-title":"Regional differences and similarities of familial amyloidotic polyneuropathy (FAP) presentation in Brazil","volume":"19","author":"Cruz MW","year":"2012","journal-title":"Amyloid"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/archneur.59.11.1771","article-title":"Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form","volume":"59","author":"Koike H","year":"2002","journal-title":"Arch Neurol"},{"issue":"Pt 7","key":"ref6","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/brain\/123.7.1495","article-title":"The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation","volume":"123","author":"Adams D","year":"2000","journal-title":"Brain"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho T","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40120-015-0031-3","article-title":"A review of tafamidis for the treatment of transthyretin-related amyloidosis","volume":"4","author":"Waddington Cruz M","year":"2015","journal-title":"Neurol Ther"},{"issue":"24","key":"ref9","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk JL","year":"2013","journal-title":"JAMA"},{"issue":"Suppl 1","key":"ref10","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","article-title":"First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy","volume":"29","author":"Adams D","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson MD","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams D","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"ref13","first-page":"7","article-title":"[Principles of the Familial transthyretin amyloidosis TTR Val30Met and the beginning of the Paramyloidosis Center of Antonio Rodrigues de Mello]","volume":"47","author":"Gomes MM","year":"2011","journal-title":"Rev Bras Neurol."},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando Y","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"sup1","key":"ref15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/13506129.2017.1292903","article-title":"Global epidemiology of transthyretin hereditary amyloid polyneuropathy: a systematic review","volume":"24","author":"Schmidt H","year":"2017","journal-title":"Amyloid"},{"issue":"6","key":"ref16","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ajmg.1320600606","article-title":"Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in P\u00f3voa do Varzim and Vila do Conde (north of Portugal)","volume":"60","author":"Sousa A","year":"1995","journal-title":"Am J Med Genet"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13506120802193720","article-title":"Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population","volume":"15","author":"Hellman UAFB-P C","year":"2008","journal-title":"Amyloid"},{"issue":"11","key":"ref18","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.40.11.e120","article-title":"Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families","volume":"40","author":"Plant\u00e9-Bordeneuve V","year":"2003","journal-title":"J Med Genet"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1468-1331.2008.02429.x","article-title":"Penetrance estimation of TTR familial amyloid polyneuropathy (type I) in Brazilian families","volume":"16","author":"Saporta MA","year":"2009","journal-title":"Eur J Neurol"},{"key":"ref20","author":"Schmidt H","year":"2016"},{"issue":"Pt 4","key":"ref21","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/brain\/113.4.903","article-title":"Type I familial amyloid polyneuropathy. A pathological study of the peripheral nervous system","volume":"113","author":"Sobue G","year":"1990","journal-title":"Brain"},{"issue":"Pt 10","key":"ref22","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1093\/brain\/122.10.1951","article-title":"Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features","volume":"122","author":"Misu K","year":"1999","journal-title":"Brain"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","article-title":"Familial amyloid polyneuropathy","volume":"10","author":"Plant\u00e9-Bordeneuve V","year":"2011","journal-title":"Lancet Neurol"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/ejhg.2010.36","article-title":"TTR familial amyloid polyneuropathy: does a mitochondrial polymorphism entirely explain the parent-of-origin difference in penetrance?","volume":"18","author":"Bona\u00efti B","year":"2010","journal-title":"Eur J Hum Genet"},{"issue":"sup1","key":"ref25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/13506129.2017.1292902","article-title":"Epidemiological and clinical characteristics of persons with transthyretin hereditary amyloid polyneuropathy: a global synthesis of 532 cases","volume":"24","author":"Cruz MW","year":"2017","journal-title":"Amyloid"},{"issue":"sup1","key":"ref26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13506129.2017.1291423","article-title":"The demographic, genetic, and clinical characteristics of Brazilian subjects enrolled in the Transthyretin Amyloidosis Outcomes Survey","volume":"24","author":"Cruz MW","year":"2017","journal-title":"Amyloid"},{"issue":"Pt 4","key":"ref27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1469-1809.2008.00439.x","article-title":"On the origin of the transthyretin Val30Met familial amyloid polyneuropathy","volume":"72","author":"Zaros C","year":"2008","journal-title":"Ann Hum Genet"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.2003.014803","article-title":"Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy","volume":"41","author":"Ohmori H","year":"2004","journal-title":"J Med Genet"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/nrcardio.2010.67","article-title":"Transthyretin-related amyloidoses and the heart: a clinical overview","volume":"7","author":"Rapezzi C","year":"2010","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s004390050199","article-title":"Revised transthyretin Ile 122 allele frequency in African-Americans","volume":"98","author":"Jacobson DR","year":"1996","journal-title":"Hum Genet"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13506120500107162","article-title":"A prospective evaluation of the transthyretin Ile122 allele frequency in an African-American population","volume":"12","author":"Yamashita T","year":"2005","journal-title":"Amyloid"},{"issue":"sup1","key":"ref32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/13506129.2017.1292239","article-title":"The demographic, genetic, and clinical characteristics of Latin American subjects enrolled in the Transthyretin Amyloidosis Outcomes Survey","volume":"24","author":"Cruz MW","year":"2017","journal-title":"Amyloid"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1468-1331.2004.00941.x","article-title":"Phenotypic expression of familial amyloid polyneuropathy in Brazil","volume":"12","author":"Bittencourt PL","year":"2005","journal-title":"Eur J Neurol"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mus.20644","article-title":"Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal","volume":"35","author":"Concei\u00e7\u00e3o I","year":"2007","journal-title":"Muscle Nerve"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.24519","article-title":"Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France","volume":"78","author":"Mariani LL","year":"2015","journal-title":"Ann Neurol"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","article-title":"Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas","volume":"83","author":"Koike H","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s00415-013-7124-7","article-title":"Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy","volume":"260","author":"Dohrn MF","year":"2013","journal-title":"J Neurol"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","article-title":"Hereditary ATTR amyloidosis: a single-institution experience with 266 patients","volume":"22","author":"Swiecicki PL","year":"2015","journal-title":"Amyloid"},{"issue":"3","key":"ref39","first-page":"408","article-title":"A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade C","year":"1952","journal-title":"Brain"},{"issue":"7","key":"ref40","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archneur.62.7.1057","article-title":"Transthyretin-related familial amyloidotic polyneuropathy","volume":"62","author":"Ando Y","year":"2005","journal-title":"Arch Neurol"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmg.31.4.293","article-title":"A study of 159 Portuguese patients with familial amyloidotic polyneuropathy (FAP) whose parents were both unaffected","volume":"31","author":"Coelho T","year":"1994","journal-title":"J Med Genet"},{"issue":"sup1 Suppl 1","key":"ref42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/13506129.2012.685665","article-title":"Regional difference and similarity of familial amyloidosis with polyneuropathy in France","volume":"19","author":"Adams D","year":"2012","journal-title":"Amyloid"},{"issue":"Pt 2","key":"ref43","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/brain\/110.2.315","article-title":"Hereditary generalized amyloidosis with polyneuropathy. Clinicopathological study of 65 Japanese patients","volume":"110","author":"Ikeda S","year":"1987","journal-title":"Brain"},{"issue":"2","key":"ref44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer MS","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"ref45","first-page":"503","article-title":"Frequency of cardiovascular involvement in familial amyloidotic polyneuropathy in Brazilian patients","volume":"105","author":"Queiroz MC","year":"2015","journal-title":"Arq Bras Cardiol"},{"issue":"4","key":"ref46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/bjo.81.4.295","article-title":"Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up","volume":"81","author":"Ando E","year":"1997","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"ref47","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato L","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"ref48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jnnp-2014-308107","article-title":"CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings","volume":"86","author":"Maia LF","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"ref49","doi-asserted-by":"crossref","first-page":"O7","DOI":"10.1186\/1750-1172-10-S1-O7","article-title":"The phenotypical expression of an European inherited TTR amyloidosis in Brazil","volume":"10","author":"Cruz MW","year":"2015","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"ref50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12153","article-title":"\u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy","volume":"21","author":"Concei\u00e7\u00e3o I","year":"2016","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"4","key":"ref51","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1085-9489.2004.09405.x","article-title":"Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies","volume":"9","author":"Vital C","year":"2004","journal-title":"J Peripher Nerv Syst"},{"issue":"4","key":"ref52","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/13506120903421850","article-title":"Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type","volume":"16","author":"Amaral B","year":"2009","journal-title":"Amyloid"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10072-016-2760-1","article-title":"Minor salivary gland biopsy for the diagnosis of familial amyloid polyneuropathy","volume":"38","author":"Eduardo FP","year":"2017","journal-title":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"issue":"407","key":"ref54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1126\/scitranslmed.aam7621","article-title":"Peptide probes detect misfolded transthyretin oligomers in plasma of hereditary amyloidosis patients","volume":"9","author":"Schonhoft JD","year":"2017","journal-title":"Sci Transl Med"},{"issue":"5","key":"ref55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","article-title":"Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy","volume":"88","author":"Cortese A","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"ref56","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","article-title":"Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)","volume":"69","author":"Plant\u00e9-Bordeneuve V","year":"2007","journal-title":"Neurology"},{"issue":"21","key":"ref57","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis","volume":"66","author":"Gertz MA","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"ref58","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: issues and challenges","volume":"21","author":"Carvalho A","year":"2015","journal-title":"Liver Transpl"},{"issue":"3","key":"ref59","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1399-0004.1991.tb03085.x","article-title":"Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)","volume":"40","author":"Holmgren G","year":"1991","journal-title":"Clin Genet"},{"issue":"1","key":"ref60","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/jlts.2002.29764","article-title":"Results of liver transplantation for familial amyloid polyneuropathy type I in Brazil","volume":"8","author":"Bittencourt PL","year":"2002","journal-title":"Liver Transpl"},{"issue":"8853","key":"ref61","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","article-title":"Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis","volume":"341","author":"Holmgren G","year":"1993","journal-title":"Lancet"},{"issue":"9","key":"ref62","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/00007890-199511150-00009","article-title":"Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients","volume":"60","author":"Suhr OB","year":"1995","journal-title":"Transplantation"},{"issue":"1","key":"ref63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/00007890-199707150-00014","article-title":"Progression of ventricular wall thickening after liver transplantation for familial amyloidosis","volume":"64","author":"Dubrey SW","year":"1997","journal-title":"Transplantation"},{"issue":"2","key":"ref64","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00007890-199807270-00016","article-title":"Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis","volume":"66","author":"Stangou AJ","year":"1998","journal-title":"Transplantation"},{"issue":"9","key":"ref65","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative?","volume":"99","author":"Ericzon BG","year":"2015","journal-title":"Transplantation"},{"issue":"1","key":"ref66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/13506129.2014.989318","article-title":"Impact of liver transplantation on the natural history of oculopathy in Portuguese patients with transthyretin (V30M) amyloidosis","volume":"22","author":"Beir\u00e3o JM","year":"2015","journal-title":"Amyloid"},{"issue":"1","key":"ref67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40120-016-0040-x","article-title":"Mechanism of action and clinical application of Tafamidis in hereditary transthyretin amyloidosis","volume":"5","author":"Coelho T","year":"2016","journal-title":"Neurol Ther"},{"issue":"11","key":"ref68","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho T","year":"2013","journal-title":"J Neurol"},{"issue":"3","key":"ref69","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2017.1357545","article-title":"Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years","volume":"24","author":"Barroso FA","year":"2017","journal-title":"Amyloid"},{"issue":"3","key":"ref70","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","article-title":"Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy","volume":"23","author":"Waddington Cruz M","year":"2016","journal-title":"Amyloid"},{"issue":"6","key":"ref71","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s12265-013-9512-x","article-title":"Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis","volume":"6","author":"Merlini G","year":"2013","journal-title":"J Cardiovasc Transl Res"},{"issue":"12","key":"ref72","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ene.12225","article-title":"Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron P","year":"2013","journal-title":"Eur J Neurol"},{"issue":"1","key":"ref73","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2017.1301419","article-title":"Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial","volume":"24","author":"Keohane D","year":"2017","journal-title":"Amyloid"},{"issue":"6","key":"ref74","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1517\/14656566.2016.1145664","article-title":"TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies","volume":"17","author":"Adams D","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"ref75","author":"Whelan CJ"},{"issue":"sup1 Suppl 1","key":"ref76","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/13506129.2012.673140","article-title":"Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy","volume":"19","author":"Ackermann EJ","year":"2012","journal-title":"Amyloid"},{"issue":"3","key":"ref77","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","article-title":"Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides","volume":"23","author":"Ackermann EJ","year":"2016","journal-title":"Amyloid"},{"issue":"9","key":"ref78","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho T","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"ref79","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr OB","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"16 Suppl","key":"ref80","article-title":"Phase 2 Open-Label Extension (OLE) Study of Patisiran, an Investigational RNA interference (RNAi) Therapeutic for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (S27.004)","volume":"88","author":"Adams D","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"ref81","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso I","year":"2010","journal-title":"J Transl Med"},{"key":"ref82","article-title":"Tolerability and efficacy of a combination of doxycycline and TUDCA in patients with Transthyretin Amyloid Cardiomyopathy","year":"2013","journal-title":"Clinical Trials gov NCT01855360"},{"key":"ref83","article-title":"Safety, efficacy and pharmacokinetics of doxycycline plus tauroursodeoxycholic acid in transthyretin amyloidosis","year":"2010","journal-title":"Clinical-Trials gov NCT01171859"},{"key":"ref84","article-title":"Phase 1\/2, open label, dose escalation study of NEOD001 in subjects with light chain (AL) amyloidosis","author":"Therapeutics P","year":"2012","journal-title":"Clinical-Trials gov NCT01707264"},{"key":"ref85","article-title":"A study to evaluate the safety of GSK2398852 when co-administered with GSK2315698 in patients with systemic amyloidosis","year":"2013","journal-title":"ClinicalTrials gov NCT017777243"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/anp\/v76n9\/0004-282X-anp-76-09-0609.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T12:59:01Z","timestamp":1542027541000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-282X2018000900609&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":85,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["S0004-282X2018000900609"],"URL":"https:\/\/doi.org\/10.1590\/0004-282x20180094","relation":{},"ISSN":["1678-4227","0004-282X"],"issn-type":[{"value":"1678-4227","type":"electronic"},{"value":"0004-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}